CN115379855A - 稳定的igg4抗体及其用途 - Google Patents

稳定的igg4抗体及其用途 Download PDF

Info

Publication number
CN115379855A
CN115379855A CN202180023859.2A CN202180023859A CN115379855A CN 115379855 A CN115379855 A CN 115379855A CN 202180023859 A CN202180023859 A CN 202180023859A CN 115379855 A CN115379855 A CN 115379855A
Authority
CN
China
Prior art keywords
antibody
igg4
disease
igg4 antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180023859.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·W·汉洛滕
W·达尔阿夸
S·阿胡佳
彭莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CN115379855A publication Critical patent/CN115379855A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180023859.2A 2020-03-31 2021-03-29 稳定的igg4抗体及其用途 Pending CN115379855A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063002631P 2020-03-31 2020-03-31
US63/002631 2020-03-31
PCT/IB2021/052589 WO2021198880A1 (en) 2020-03-31 2021-03-29 Stabilized igg4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN115379855A true CN115379855A (zh) 2022-11-22

Family

ID=77928189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023859.2A Pending CN115379855A (zh) 2020-03-31 2021-03-29 稳定的igg4抗体及其用途

Country Status (5)

Country Link
US (1) US20250270325A1 (enExample)
EP (1) EP4126045A4 (enExample)
JP (1) JP2023519602A (enExample)
CN (1) CN115379855A (enExample)
WO (1) WO2021198880A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124451A1 (en) * 2012-02-22 2013-08-29 Ucb Pharma S.A. Sequence symmetric modified igg4 bispecific antibodies
JP2013538052A (ja) * 2010-08-20 2013-10-10 ユセベ ファルマ ソシエテ アノニム クラスＩｇＧ４の改良型抗体
CN104321341A (zh) * 2012-02-22 2015-01-28 Ucb医药有限公司 序列对称性的修饰的IgG4双特异性抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI635098B (zh) * 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
KR20190057083A (ko) * 2016-10-06 2019-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 공정 불순물에 대한 결합이 감소된 항체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538052A (ja) * 2010-08-20 2013-10-10 ユセベ ファルマ ソシエテ アノニム クラスＩｇＧ４の改良型抗体
WO2013124451A1 (en) * 2012-02-22 2013-08-29 Ucb Pharma S.A. Sequence symmetric modified igg4 bispecific antibodies
CN104321341A (zh) * 2012-02-22 2015-01-28 Ucb医药有限公司 序列对称性的修饰的IgG4双特异性抗体
US20190202937A1 (en) * 2012-02-22 2019-07-04 Ucb Biopharma Sprl Sequence Symmetric Modified IGG4 Bispecific Antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARIE-PAULE LEFRANC 等: ""IMGT® Nomenclature of Engineered IGHG Variants Involved in Antibody Effector Properties and Formats"", ANTIBODIES, vol. 11, no. 65, 18 October 2022 (2022-10-18), pages 1 - 45 *

Also Published As

Publication number Publication date
EP4126045A1 (en) 2023-02-08
WO2021198880A1 (en) 2021-10-07
EP4126045A4 (en) 2024-04-10
JP2023519602A (ja) 2023-05-11
US20250270325A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
US11041022B2 (en) Humanized antibodies against c-Kit
JP6412083B2 (ja) 安定なＩｇＧ４抗体
US11739143B2 (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
US9085625B2 (en) Antibody variants having modifications in the constant region
US20210047404A1 (en) Cd33 antibodies and use of same to treat cancer
US20220372162A1 (en) Pct/us2020/066088
CA3183835A1 (en) High affinity antibodies targeting tau phosphorylated at serine 413
CN115379855A (zh) 稳定的igg4抗体及其用途
CN114751986B (zh) 中和新冠病毒的多特异性抗体
EP3623383A1 (en) Improved bispecific flt3xcd3 antigen binding proteins
JP2023523794A (ja) 人工操作免疫グロブリン
US20250122286A1 (en) Antibody optimization
EP4357361A9 (en) Anti-il-36r antibody and use thereof
HK40095627A (zh) 用於治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
HK40115449A (zh) 用於治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
HK1163128A (en) Igg4 antibody variants having modifications in the constant region
HK1163128B (en) Igg4 antibody variants having modifications in the constant region

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination